CHINOOK TRANSPORTATION SERVICES
CHINOOK TRANSPORTATION SERVICES
Industry:
Food Delivery Logistics Transportation
Address:
Yakima, Washington, United States
Country:
United States
Website Url:
http://www.chinookts.com
Status:
Active
Contact:
1-888-222-1019
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS
Official Site Inspections
http://www.chinookts.com
- Host name: ngcluster.msg.chrl.nc.charter.net
- IP address: 47.43.22.53
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Chinook Transportation Services"
Novartis completes acquisition of Chinook Therapeutics
Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance. Learn about our …See details»
Chinook Therapeutics - Crunchbase Company Profile & Funding
Www.chinooktx.com ; 13,998; Highlights. Acquisitions 1. obfuscated. Total Funding Amount . Unlock for free . Contacts 194. Employee Profiles 7. ... Furthermore, being part of a larger …See details»
Chinook Therapeutics - LinkedIn
Chinook Therapeutics | 12,608 followers on LinkedIn. Changing the Course of Kidney Care | We officially combined with Novartis to further strengthen our scientific capabilities and treatments …See details»
Chinook Therapeutics
Nov 12, 2024 Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases.See details»
Chinook Therapeutics, Inc. Information - RocketReach
Chinooktx.com; 1 604396XXXX; View Similar People. Related Companies RareCyte, Inc. 70 $3m InBios International, Inc. 74 $14.3m Axio Research. 20 $10m Shape Therapeutics Inc. 146 Kelley-Ross Pharmacy Group. 51 $22.4m ...See details»
Chinook Therapeutics, a Novartis Company Overview
Chinook Therapeutics is now a Novartis Company! On August 11, 2023, Novartis completed its acquisition of Chinook. Follow the Novartis channel or visit www.novartis.com to stay updated …See details»
Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 ...
Feb 27, 2023 Under Andrew’s leadership, Chinook will develop its go-to-market strategy and build a commercial organization in preparation for the potential launch of atrasentan and future …See details»
Chinook Therapeutics Company Profile | Management and
[email protected]: Chinook Therapeutics Top Competitors. Company Employees Revenue Top technologies; HiFiBiO Therapeutics Inc. 88: $22.7 M: HBM Holdings Ltd. 167: $54 M: …See details»
Chinook Board CORPORATE GOVERNA - investors.chinooktx.com
Management (either directly or as a partner, stockholder or officer of an organization that has a relationship with us), or that would interfere with the director exercising independent judgment …See details»
Chinook Therapeutics - Overview, News & Similar companies
Chinook Shareholder Notice New York, New York--(Newsfile Corp. - September 3, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against …See details»
Chinook Therapeutics Announces Upcoming Presentations at the …
Feb 28, 2023 To learn more, visit www.chinooktx.com. Cautionary Note on Forward-Looking Statements Certain of the statements made in this press release are forward looking, including …See details»
Chinook Therapeutics - Company Profile - Tracxn
Aug 17, 2021 Email ID: *****@chinooktx.com; Key Metrics. Latest Funding Round. Post IPO, Aug 17, 2020, $115M. Investors. Rock Springs Capital & 13 more. Ranked. 13 th among 97 …See details»
Chinook Therapeutics Enters into Agreement to be Acquired by …
Jun 12, 2023 Chinook Therapeutics, Inc. Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value …See details»
Novartis
Patient organization funding Payments to healthcare professionals Public policy A living wage A safe workplace Animal research Environmental, social and governance. Learn about our …See details»
Chinook Therapeutics - Craft
Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. It offers atrasentan, a potent and selective endothelin A (ETA) receptor antagonist; zigakibart (BION-1301), is an anti-APRIL monoclonal antibody; and CHK-336, an oral small molecule lactate dehydrogenase (LDHA) inhibitor.See details»
Chinook Therapeutics Announces the Appointment of Andrew …
Feb 15, 2023 He joins Chinook from Aimmune Therapeutics, where he most recently served as president and CEO and led the organization’s integration into its new parent company, Nestlé …See details»
Chinook Therapeutics, IgA Nephropathy Foundation and Komodo …
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative …See details»
Chinook Therapeutics Inc. - Cruelty Free Investing
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Company Website: https://www.chinooktx.comSee details»
Chinook Therapeutics Provides Business Update and Reports Third …
Sep 30, 2022 SEATTLE, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and …See details»
Chinook Therapeutics, Inc. Email Format | chinooktx.com Emails
The most common Chinook Therapeutics, Inc. email format is [first_initial][last] (ex. [email protected]), which is being used by 100.0% of Chinook Therapeutics, Inc. work …See details»